Review Article
An Overview of Systematic Reviews of Using Chinese Medicine to Treat Polycystic Ovary Syndrome
Table 11
GRADE quality-of-evidence ratings for adverse effects.
| | Included systematic reviews | Number of studies included | Adverse effects effect (95% CI) | GRADE quality of evidence | Relegation factors |
| | Yan Lun et al. 2015 [17] | 4 | OR = 0.19, 95% CI (0.08, 0.46) | Low | ①⑤ | | Xiao Chao 2016 [18] | 4 | RD = –0.05, 95% CI (–0.13, 0.03) | Very low | ①②⑤ | | Li Nan et al. 2017 [19] | 3 | OR = 0.07, 95% CI (0.02, 0.23) | Very low | ①②④⑤ | | Xu LiFang et al. 2018 [21] | 10 | OR = 0.26, 95% CI (0.09, 0.80) | Low | ①⑤ | | Ji Lin 2019 [26] | 13 | OR = 0.26, 95% CI (0.12, 0.55) | Very low | ①②⑤ | | Dong YuFang 2020 [29] | 8 | RR = 0.12, 95% CI (0.06, 0.25) | Low | ①④ | | Lin BeiBei 2020 [32] | 13 | RR = 0.36, 95% CI (0.20, 0.63) | Low | ①④ |
|
|
Note. CI: confidence interval; OR: odds ratio; RR: relative risk; ①: limitation; ②: inconsistency; ③: indirectness; ④: publication bias; ⑤: imprecision.
|
